Adjunctive LDL-Lowering Therapies
Cross-source consensus on Adjunctive LDL-Lowering Therapies from 1 sources and 4 claims.
1 sources · 4 claims
Uses
Evidence quality
Highlighted claims
- Non-statin LDL-lowering therapy use was rare despite statin barriers and suboptimal LDL control. — Statin prescription rates for prevention of atherosclerotic cardiovascular disease in adults 40–75 years old with type 1 diabetes
- Ezetimibe was prescribed to 4.1% of patients. — Statin prescription rates for prevention of atherosclerotic cardiovascular disease in adults 40–75 years old with type 1 diabetes
- Only one patient used a PCSK9 inhibitor, and no patients received bempedoic acid. — Statin prescription rates for prevention of atherosclerotic cardiovascular disease in adults 40–75 years old with type 1 diabetes
- Among patients with statin intolerance or refusal, alternative LDL-lowering therapy use was very low. — Statin prescription rates for prevention of atherosclerotic cardiovascular disease in adults 40–75 years old with type 1 diabetes